The three most common used anti-TNF-α agents are: infliximab (chimeric mouse/human) administered previously in patients with CVID, ataxia-telangiectasia, leucocyte adhesion deficiency, STAT3 GOF mutations, NEMO deficiency; adalimumab (human) in patients with LBRA mutation, CVID and STAT3 GOF mutations and etanercept in patients with CVID (141). Here, STAT3 is linked to Ataxia-telangiectasia.